MBX Biosciences Inc. (NASDAQ: MBX) dosed the first participant in a Phase 1 trial of MBX 4291, an obesity treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE